Boston, MA 02/18/2014 (wallstreetpr) – Occidental Petroleum Corporation (NYSE:OXY) the oil and gas exploration and production company began Feb 2014, with a firm footing, with good fourth quarter results which beat estimates. Only wrong note for the quarter for OXY was the drop in production. The first week saw OXY committing to NuStar to use its 200mile pipeline in Texas by the second quarter of next fiscal. Next, was an assets sale at Hugoton gas was expected to bring in $1.4 billion which led to OXY consolidating its assets through and spinning-out a trading company exclusively engage in natural gas producer and remain one of the largest in the state to do so. Amidst all of the restructuring and consolidation, apparently Kyle Bass, the high-profile hedge fund investor announced holding considerably stake in some of the energy companies one of which is Occidental Petroleum Corporation (NYSE:OXY). Kyle Bass move follows his perfectly-timed exit from Herbalife and is now focused on Energy as well as Real Estate companies to move his abundant funds.
KeyCorp (NYSE:KEY) is on a rough ride as shares slumped sharply following the fourth quarter results, which is failed to deliver, given its inability to control rising prices.
Merck & Co., Inc. (NYSE:MRK) the pharma company which makes consumer care products and biologic therapies has decided to shed some weight. Rightfully, so claim most analysts who have been watching this multi-national grow into the $162.25 billion dollar company it is today. Coming up for heave-off is consumer brands division. As per estimated valuations, the division is worth over $10 billion. In-line with industry trend to move out of less revenue-earning divisions and consolidating high revenue sections, Merck is definitely a step away from evolving into a new form. Fortunately, for Merck & Co., Inc. (NYSE:MRK) with the vaccine and animal –health also part of its consumer brand, Financial Services provider Morgan Stanley is scouting for the perfect partner to heave-off the division on behalf of Merck & Co.
